Pharma Services Network

pharmaservicesnet.com

Since 2003, Pharma Services Network has been helping pharmaceutical, biotech, and device sponsors from around the world to identify, qualify, and engage with service providers ideally suited to their needs. We have in-depth knowledge of Internationally based CROs, Regulatory Consultants, and a host of other strategic service providers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

PHIO PHARMACEUTICALS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2020 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

Phio Pharmaceuticals Corp | October 26, 2020

news image

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually...

Read More

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

news image

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR 0.9% SODIUM CHLORIDE INJECTION

businesswire | August 31, 2023

news image

Nexus Pharmaceuticals LLC announced it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in 10mL and 20mL Single-Dose Vials. “This product is part of an expanding portfolio of products that address critical healthcare challenges,” said Omair Ahmed, Chief Operating Officer. “Sodium Chloride Injection is used to treat patients every day in every hospital in the United States. We are grateful to be able to bolste...

Read More

Pharmacy Market

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

news image

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More
news image

Pharma Tech

PHIO PHARMACEUTICALS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2020 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

Phio Pharmaceuticals Corp | October 26, 2020

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually...

Read More
news image

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More
news image

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR 0.9% SODIUM CHLORIDE INJECTION

businesswire | August 31, 2023

Nexus Pharmaceuticals LLC announced it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in 10mL and 20mL Single-Dose Vials. “This product is part of an expanding portfolio of products that address critical healthcare challenges,” said Omair Ahmed, Chief Operating Officer. “Sodium Chloride Injection is used to treat patients every day in every hospital in the United States. We are grateful to be able to bolste...

Read More
news image

Pharmacy Market

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us